Abstract
The present disclosure provides microfluidic test platforms, systems, and methods for manufacturing the disclosed test platforms. The present disclosure further provides uses of the disclosed microfluidic test platforms in personalized medicine. Specifically, in providing prognostic and therapeutic methods for determining drug sensitivity and optimizing treatment regimen for subjects suffering from a pathologic disorder, specifically, cancer.
| Original language | English |
|---|---|
| Patent number | US20210354140A1 |
| State | Published - 18 Nov 2021 |
